Bifogade filer
PDF
Kurs & Likviditet
Kalender
| 2025-02-18 | Bokslutskommuniké 2024 |
| 2024-11-07 | Kvartalsrapport 2024-Q3 |
| 2024-07-18 | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | Ordinarie utdelning ENZY 0.00 SEK |
| 2024-05-07 | Årsstämma 2024 |
| 2024-04-25 | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | Bokslutskommuniké 2023 |
| 2023-11-07 | Kvartalsrapport 2023-Q3 |
| 2023-07-18 | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | Ordinarie utdelning ENZY 0.00 SEK |
| 2023-05-04 | Årsstämma 2023 |
| 2023-04-27 | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | Bokslutskommuniké 2022 |
| 2022-11-02 | Kvartalsrapport 2022-Q3 |
| 2022-07-19 | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | Ordinarie utdelning ENZY 0.00 SEK |
| 2022-04-28 | Kvartalsrapport 2022-Q1 |
| 2022-04-28 | Årsstämma 2022 |
| 2022-02-17 | Bokslutskommuniké 2021 |
| 2021-11-02 | Kvartalsrapport 2021-Q3 |
| 2021-10-18 | Extra Bolagsstämma 2021 |
| 2021-07-16 | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | Ordinarie utdelning ENZY 0.00 SEK |
| 2021-05-05 | Årsstämma 2021 |
| 2021-04-29 | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | Bokslutskommuniké 2020 |
| 2020-11-03 | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | Kvartalsrapport 2020-Q2 |
| 2020-05-06 | Ordinarie utdelning ENZY 0.00 SEK |
| 2020-05-05 | Kvartalsrapport 2020-Q1 |
| 2020-05-05 | Årsstämma 2020 |
| 2020-02-13 | Bokslutskommuniké 2019 |
| 2019-11-05 | Kvartalsrapport 2019-Q3 |
| 2019-07-17 | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | Ordinarie utdelning ENZY 0.00 SEK |
| 2019-05-07 | Kvartalsrapport 2019-Q1 |
| 2019-05-07 | Årsstämma 2019 |
| 2019-02-19 | Bokslutskommuniké 2018 |
| 2018-10-31 | Kvartalsrapport 2018-Q3 |
| 2018-07-17 | Kvartalsrapport 2018-Q2 |
| 2018-04-27 | Ordinarie utdelning ENZY 0.00 SEK |
| 2018-04-26 | Årsstämma 2018 |
| 2018-04-26 | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | Bokslutskommuniké 2017 |
| 2017-11-01 | Kvartalsrapport 2017-Q3 |
| 2017-07-20 | Kvartalsrapport 2017-Q2 |
| 2017-04-21 | Ordinarie utdelning ENZY 0.00 SEK |
| 2017-04-20 | Kvartalsrapport 2017-Q1 |
| 2017-04-20 | Årsstämma 2017 |
| 2017-02-16 | Bokslutskommuniké 2016 |
| 2016-12-19 | Extra Bolagsstämma 2016 |
| 2016-11-03 | Kvartalsrapport 2016-Q3 |
| 2016-07-18 | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | Årsstämma 2016 |
| 2016-04-22 | Ordinarie utdelning ENZY 0.00 SEK |
| 2016-04-18 | Kvartalsrapport 2016-Q1 |
| 2016-02-16 | Bokslutskommuniké 2015 |
| 2015-10-20 | Kvartalsrapport 2015-Q3 |
| 2015-07-21 | Kvartalsrapport 2015-Q2 |
| 2015-04-22 | Ordinarie utdelning ENZY 0.00 SEK |
| 2015-04-21 | Årsstämma 2015 |
| 2015-04-21 | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | Bokslutskommuniké 2014 |
| 2014-12-19 | Extra Bolagsstämma 2014 |
| 2014-10-21 | Kvartalsrapport 2014-Q3 |
| 2014-07-22 | Kvartalsrapport 2014-Q2 |
| 2014-05-20 | Ordinarie utdelning ENZY 0.00 SEK |
| 2014-05-19 | Årsstämma 2014 |
| 2014-05-19 | Kvartalsrapport 2014-Q1 |
| 2014-02-04 | Bokslutskommuniké 2013 |
| 2013-11-13 | Kvartalsrapport 2013-Q3 |
| 2013-08-22 | Kvartalsrapport 2013-Q2 |
| 2013-05-21 | Kvartalsrapport 2013-Q1 |
| 2013-05-07 | Ordinarie utdelning ENZY 0.00 SEK |
| 2013-05-06 | Årsstämma 2013 |
| 2013-02-15 | Bokslutskommuniké 2012 |
| 2012-11-22 | Kvartalsrapport 2012-Q3 |
| 2012-08-23 | Kvartalsrapport 2012-Q2 |
| 2012-06-04 | 15-7 2012 |
| 2012-05-24 | Kvartalsrapport 2012-Q1 |
| 2012-05-16 | Kvartalsrapport 2012-Q1 |
| 2012-04-19 | Ordinarie utdelning ENZY 0.00 SEK |
| 2012-04-18 | Årsstämma 2012 |
| 2012-02-29 | Kvartalsrapport 2011-Q3 |
| 2012-02-29 | Bokslutskommuniké 2011 |
| 2011-12-22 | Kvartalsrapport 2011-Q2 |
| 2011-09-29 | Kvartalsrapport 2011-Q1 |
| 2011-09-16 | Ordinarie utdelning ENZY 0.00 SEK |
| 2011-09-15 | Årsstämma 2011 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
4 April 2022
Non-regulatory press release
Enzymatica's mouth spray to be launched in Turkey
Enzymatica's mouth spray against the common cold will be launched in Turkey, following the approval as a medical device in the country. This opens a new market of more than 80 million consumers.
The Turkish cough and cold market has an estimated worth of approximately EUR 1.1 billion and has shown a steady growth during the last years. Now Enzymatica's mouth spray against the common cold will be launched in Turkey, following the approval as a medical device by TITCK, the Turkish Medicines and Medical Devices Agency.
"Turkey is a large market with great future potential. We are happy that the product will be launched shortly, following a smooth and prompt approval process where safety and clinical performance data were reviewed", said Claus Egstrand, CEO of Enzymatica.
The product will be marketed, sold, and distributed in Turkey by Sanofi Consumer Health Care under one of its own brands.
FOR MORE INFORMATION, PLEASE CONTACT:
Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email:claus.egstrand@enzymatica.com
Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46(0) 708 55 11 85 | Email:stefan.olsson@enzymatica.com